77 related articles for article (PubMed ID: 27264833)
1. Amifostine treatment in patients with myelodysplastic syndrome.
Çetiner M; Fıratlı Tuğlular T; Özen Al Ahdab Y; Al Ahdab H; Köse M; Noyan F; Adıgüzel C; Ovalı E; Bayık M
Turk J Haematol; 2005 Sep; 22(3):117-23. PubMed ID: 27264833
[TBL] [Abstract][Full Text] [Related]
2. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.
List AF; Brasfield F; Heaton R; Glinsmann-Gibson B; Crook L; Taetle R; Capizzi R
Blood; 1997 Nov; 90(9):3364-9. PubMed ID: 9345018
[TBL] [Abstract][Full Text] [Related]
4. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
[TBL] [Abstract][Full Text] [Related]
5. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels.
Hofmann WK; Seipelt G; Ottmann OG; Kalina U; Koschmieder S; Brücher J; Frickhofen N; Klausmann M; Mitrou PS; Hoelzer D
Ann Hematol; 2000 May; 79(5):255-8. PubMed ID: 10870480
[TBL] [Abstract][Full Text] [Related]
6. Amifostine in the treatment of low-risk myelodysplastic syndromes.
Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
[TBL] [Abstract][Full Text] [Related]
7. [Study on prognostic factors in twenty-five patients with myelodysplastic syndrome].
Toyama T; Uno H; Yamashita K; Kubuki Y; Suzuki M; Maeda K; Matsuoka H; Tsubouchi H
Gan To Kagaku Ryoho; 1995 Feb; 22(2):227-32. PubMed ID: 7857097
[TBL] [Abstract][Full Text] [Related]
8. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
[TBL] [Abstract][Full Text] [Related]
9. [Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].
Dewulf G; Gouin I; Pautas E; Gaussem P; Chaïbi P; Andreux JP; Siguret V
Ann Biol Clin (Paris); 2004; 62(2):197-202. PubMed ID: 15047472
[TBL] [Abstract][Full Text] [Related]
10. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
Raza A; Qawi H; Lisak L; Andric T; Dar S; Andrews C; Venugopal P; Gezer S; Gregory S; Loew J; Robin E; Rifkin S; Hsu WT; Huang RW
Blood; 2000 Mar; 95(5):1580-7. PubMed ID: 10688811
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
Ghaddar HM; Stass SA; Pierce S; Estey EH
Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Tsiara SN; Kapsali HD; Panteli K; Christou L; Bourantas KL
J Exp Clin Cancer Res; 2001 Mar; 20(1):35-8. PubMed ID: 11370827
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.
Invernizzi R; Pecci A; Travaglino E; Gobbi PG; Malabarba L; Ramajoli I; Ascari E
Br J Haematol; 2002 Jul; 118(1):246-50. PubMed ID: 12100155
[TBL] [Abstract][Full Text] [Related]
14. [Chromosome abnormalities in myelodysplastic syndrome].
Fujita K; Mori H; Niikura H; Terada H; Shinohara T
Rinsho Byori; 1990 Aug; 38(8):911-6. PubMed ID: 2232253
[TBL] [Abstract][Full Text] [Related]
15. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome.
Dalamaga M; Karmaniolas K; Chamberland J; Nikolaidou A; Lekka A; Dionyssiou-Asteriou A; Mantzoros CS
Metabolism; 2013 Dec; 62(12):1830-9. PubMed ID: 24140093
[TBL] [Abstract][Full Text] [Related]
16. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
17. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.
Yilmaz A; Kaufmann CC; Binder C; Wörmann B; Haase D
Ann Hematol; 2001 Jan; 80(1):53-7. PubMed ID: 11233778
[TBL] [Abstract][Full Text] [Related]
18. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
19. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
20. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
